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ABSTRACT
The aim of this work was to evaluate the contribution of
real-world evidence (RWE) in changing anti-vascular
endothelial growth factor (VEGF) therapy treatment
practices and improving real-world treatment strategies for
neovascular age-related macular degeneration (nAMD).
A PubMed literature search was performed to review the
large number of English-language studies conducted to
investigate the real-world effectiveness of anti-VEGF
(aflibercept and ranibizumab) treatment paradigms
available for nAMD.
The evidence for pro re nata (PRN), treat-and-extend
(T&E) and fixed bimonthly dosing regimens for anti-VEGF
treatment of nAMD were reviewed and findings are
summarised. RWE demonstrated that T&E regimens
optimise visual outcomes while reducing burden on
patients, clinics and physicians, compared with both
fixed-dose and PRN regimens.
RWE has helped to develop and improve real-world
treatment strategies in nAMD, with the aim of optimising
visual outcomes and reducing treatment burden in clinical
practice. Of the various regimens, a T&E regimen is most
likely to adequately balance clinical outcomes and
treatment burden for patients with nAMD.
INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blindness in developed countries,
affecting up to 18% of adults aged over
85 years.1–5 Without treatment, the progressive
loss of central visual acuity (VA) that charac-
terises late-stage AMD leads to severe and per-
manent visual impairment and legal blindness.
This can have a major impact on patients’ quality
of life, ability to perform day-to-day activities
and functional independence, contributing to
considerable emotional impact.5–8 Delay in initi-
ating nAMD treatment and poor patient adher-
ence can contribute to suboptimal outcomes,
highlighting the need for management
approaches that incorporate timely and effective
treatment at intervals to match the needs of each
patient.9 10 Prior to the early 2000s, treatment
options for neovascular AMD (nAMD) were lim-
ited to laser photocoagulation and photodynamic
therapy (PDT), but these are now redundant in
current clinical practice in the context of newer
treatment options because of the relatively poor
visual outcomes and risk of adverse events.10–13
Confirmation that vascular endothelial growth
factor (VEGF) is a key pathogenic factor in the
development of nAMD12 was a milestone that
subsequently led to highly effective, novel anti-
VEGF therapies (including the RNA oligonucleo-
tide, pegaptanib and particularly the anti-VEGF
monoclonal antibodies, ranibizumab and intravi-
treal aflibercept).10 11 13–17 Ranibizumab, first
approved in 2006, prevented vision loss and led
to gains in VA compared with either PDT or
sham injections in two key phase III clinical
trials, ANCHOR and MARINA, with monthly
intravitreal injections.15 16 Intravitreal afliber-
cept, a soluble decoy VEGF receptor,18 was
approved in 2011 for the treatment of nAMD
as a result of significant VA gains in the phase
III VIEW 1 and 2 trials, using a regimen of three
initial monthly injections followed by injections
every 8 weeks in Year 1 and every 12 weeks or
more in Year 2 and beyond, based on visual/ana-
tomical outcomes evaluated monthly.13 19 20
Although randomised controlled trials (RCTs) such
as ANCHOR, MARINA and VIEW are considered
the ‘gold standard’ for establishing efficacy and safety,
their relevance to real-life clinical practice is restricted
by the selective trial populations and controlled
environment.21 Real-world evidence (RWE) gener-
ated in clinical practice can offer additional insights
into the effectiveness, safety and practicality of treat-
ments in heterogeneous patient populations, and can
highlight the influence of treatment patterns on real-
world adherence, persistence and outcomes.10 21
The aim of this article is to evaluate the contribu-
tion of RWE in changing treatment practices with
anti-VEGF therapy in nAMD and to examine its role
in optimising anti-VEGF treatment regimens to
maintain the best long-term visual outcomes for
patients, while reducing the burden of therapy.
METHODS
This narrative review was informed by a structured
literature search to include evidence in an unbiased
manner. A search of the PubMed database was per-
formed on 5 July 2018, using the following search
terms: (long-term OR real-life OR longitudinal OR
cohort OR clinical experience OR open-label OR
real-world OR database OR non-interventional OR
observational) NOT (randomised OR randomised
OR tumour OR tumour) AND (ranibizumab OR
Lucentis OR aflibercept OR Eylea OR bevacizumab
ORAvastin) AND age-related macular degeneration
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NOT (Review[ptyp]) NOT diabetic macular oedema, and was
limited to English language. The literature search results were
reviewed, and relevant articles identified based on their titles. For
any articles where the relevance was unclear, abstracts and full
manuscripts were reviewed to ensure that data regarding long-
term VA and treatment regimens over 12-month periods were
included. Additionally, reference lists from studies identified dur-
ing the literature search were reviewed and any further relevant
articles and conference abstracts were included (online supple
mental tables 1 and 2 provide a full summary of relevant data
from the identified literature).
Articles identified during the literature search were selected for
discussion in this review based on the relevance to changes in
clinical practice and weight of the evidence described. As such,
this review is intended to provide a narrative description of the
evolutions of treatment paradigms in nAMD, rather than serve as
a systematic summary of all available data on the topic.
To support analysis of the outcomes reported in the identified
articles, and place the findings in the context of the current
nAMD landscape, two further papers were considered, which
report comparisons between data for current anti-VEGF thera-
pies and those in development22 and RWE from nearly 50 000
eyes with nAMD.23
RESULTS
Since the approval of ranibizumab and intravitreal aflibercept for
the treatment of nAMD, a growing body of evidence has demon-
strated the real-world effectiveness of anti-VEGF therapy, sup-
porting the optimisation of treatment regimens.
Anti-VEGF treatment in pro re nata (PRN; as needed) regimens
The initial approval of ranibizumab in a fixed monthly regimen
was based on the phase III ANCHOR and MARINA trials that
enrolled >1000 patients and demonstrated gains in VA of +7.2
and +11.3 letters after 1 year with 0.5 mg ranibizumab monthly
dosing.15 16 However, the requirement for monthly dosing was
associated with a high treatment burden for patients and health-
care systems, resulting in difficulty adhering to treatment in real-
world settings and driving the move towards PRN regimens.24
With PRN treatment, patients aremonitored frequently (typically
monthly), but only treated when disease reactivation, or worsen-
ing, is detected (decrease in VA and/or anatomical outcomes as
measured by optical coherence tomography or fluorescein
angiography).10 PRN regimens may be initiated after initial
fixed doses have achieved maximum VA gains and disease
stability.20 25
Subsequent RCTs evaluated the efficacy of PRN regimens
compared with monthly injections for maintaining VA gains,
with the aim of reducing treatment burden.26 27 The largest
were the phase III CATTand HARBOR trials, in which clinically
meaningful increases in VA were observed after 12 months of
ranibizumab PRN treatment (+6.8 and +8.2 letters, respec-
tively). However, these findings were statistically non-inferior
to the letter changes in the monthly dosing arms in the CATT
trial, and did not reach the prespecified non-inferiority compar-
ison in the HARBOR trial (+8.5 and +10.1 letters,
respectively).26 28 Since initial approval, the ranibizumab label
has been updated to monthly injections initially, until maximum
VA is achieved and/or there are no signs of disease activity,
followed by PRN with monitoring and injections at the physi-
cian’s discretion, based on disease activity. The ranibizumab label
also provides guidance on use as part of a treat-and-extend (T&E)
regimen and, once maximum VA is achieved and/or there are no
signs of disease activity, treatment intervals can be extended
stepwise (by no more than 2 weeks at a time for nAMD) until
signs of disease activity or visual impairment recur.25
The 62 publications describing outcomes of anti-VEGF PRN
regimens in routine clinical practice are outlined in online supple
mental table 1. Of note, two meta-analyses examining the effec-
tiveness of ranibizumab in real-world studies were identified.
Guo et al reported an improvement of +4.85 letters after
1 year in 37 observational studies with ranibizumab treatment
(which included fixed-dose and PRN regimens).29 Similarly, Kim
et al reported an increase of +3.5 letters at Year 1 with ranibizu-
mab PRN regimens (N=20 247); however, this was not main-
tained, reducing to +1.3 letters at Year 2 and−1.9 letters by Year
3 (N=14 408 and 11 714, respectively).30
Three articles reported outcomes for studies including >1000
patients on PRN regimens (AURA, LUMINOUS and IRIS) and, in
all, improvements in VA were observed with ranibizumab PRN
treatment at 1 year compared with baseline.31–33 However, in
AURA, which continued beyond 1 year of treatment, the initial
gains in VA observed after 4 months with initial ranibizumab
monthly injections, were not maintained at Year 1 and continued
to decline towards the end of Year 2.31 In studies continuing
beyond 3 years, declining VA with anti-VEGF PRN regimens
was observed over the long term.34–42 Furthermore, in a small
study in which initial VA gains were maintained for up to 5 years,
the number of injections administered annually increased in later
years (median of seven injections in Year 5 vs four injections in
Years 2–4).43 This observation is consistent with other studies
that indicated that, despite treatment being administered on
a PRN basis, a higher number of injections is independently
correlated with improved VA for patients with nAMD treated
with ranibizumab.33 44–47
RWE has highlighted the challenges associated with matching
the outcomes observed in RCTs with PRN regimens in routine
clinical practice, including physician preference, under-treatment
and patient adherence.10 22 31 32 This drove efforts to investigate
alternative anti-VEGF regimens, to maximise and maintain VA
gains for all patients.
Fixed bimonthly dosing
Intravitreal aflibercept was initially approved in a bimonthly regi-
men after three initial loading doses, supported by the phase III
VIEW 1 and 2 trials, in which similar mean gains in VA were
observed with 4-weekly and 8-weekly dosing (9.3 letter gain with
4-weekly dosing and 8.4 with 8-weekly dosing of intravitreal
aflibercept 2 mg).19
Nine articles describing outcomes of bimonthly fixed-dose
anti-VEGF regimens in routine clinical practice were identified,
all of which investigated the effectiveness of intravitreal afliber-
cept in a bimonthly dosing regimen following three initial loading
doses (online supplemental table 1). No RWE on the effectiveness
of fixed bimonthly dosing with ranibizumab was identified.
Regardless of study type, intravitreal aflibercept administered in
a bimonthly regimen following three initial monthly doses was
consistently associated with gains in VA at Year 1, with improve-
ments in vision ranging from +3.0 to +8.0 letters from
baseline.48–56 Talks et al concluded that the VA gains observed
were comparable to those reported in the VIEW 1 and 2 phase III
trials.48
Several real-world studies have compared the effectiveness of intra-
vitreal aflibercept bimonthly treatment with intravitreal aflibercept
and ranibizumab PRN regimens. In PERSEUS, when both treatment-
naïve and -experienced patients were considered, those receiving
regular bimonthly intravitreal aflibercept achieved significantly
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greater improvements in VA than those in the irregular treatment
cohort (+6.1 letters vs +1.5 letters, respectively, at Year 1;
p=0.008).49 Similar observations were made in the RAINBOW
study; however, in both studies, the irregular cohorts did not have
a strict definition and, although a PRN regimen was assumed by the
authors, the number of injections was lower than is recommended by
EURETINAguidelines.13 49 56 In a retrospective analysis of electronic
medical records in the UK, patients receiving intravitreal aflibercept
(initial loading doses followed by fixed bimonthly dosing) achieved
gains of+5.93 letters atYear1, comparedwith+2.55 letters for those
receiving ranibizumab (initial loadingdoses, thenPRN), despite lower
baseline VA for patients initiating ranibizumab.57
Theeffectivenessof fixedbimonthlydosinghas beendemonstrated
in routine clinical practice, with evidence indicating improved out-
comes compared with PRN regimens. However, fixed treatment is
still associated with considerable treatment burden.10 48–56
T&E regimens
T&E regimens aim to personalise treatment, further reducing the
burden on patients and healthcare systems, by allowing variation
in treatment interval based on the individual patient’s disease
activity, while optimising anti-VEGF efficacy compared with
PRN regimens. Although specific dosing schedules may vary
according to drug, after initial loading doses, T&E regimens
typically involve treatment administration at every scheduled
clinic visit, with incremental increase or decrease in the interval
between each visit according to anatomic outcomes and VA—the
objective being to maximise the interval between injections with-
out disease recurrence.10 20 25
RCTs have demonstrated good visual outcomes for patients
receiving T&E regimens with anti-VEGF therapies. T&E regi-
mens with ranibizumab were shown to be non-inferior to
monthly dosing in the phase III TREND and TREX-AMD
RCTs, with +6.2 vs +8.1 letter in TREND (Year 1) and +8.7 vs
+10.5 letter in TREX (Year 2) gains, respectively.58 59 Similarly,
the second year of the phase III RCTs, VIEW 1 and 2, and the
2-year prospective, open-label ATLAS study provided evidence
for the ability to extend intravitreal aflibercept beyond bimonthly
dosing to 12-week intervals.60 61 Patients receiving intravitreal
aflibercept in a T&E regimen in the RCTALTAIR achieved gains
in VA of +9.0 and +8.4 letters at Year 1 for 2-week and 4-week
adjustment periods, respectively.62
Twenty-five articles describing outcomes with T&E regimens
with ranibizumab, intravitreal aflibercept and bevacizumab in rou-
tine clinical practice were identified (online supplemental table 2).
Although T&E dosing, according to the aflibercept label, was not
strictly adhered to in all studies, together, they confirm that a real-
world, T&E protocol with anti-VEGFs can improve VA over
periods of up to 3 years in patients with nAMD.50 61 63–78
Meta-analyses have supported initial observations that better
visual outcomes are achieved with T&E regimens while reducing
the burden on patients, clinics and physicians.30 Furthermore,
a meta-analysis of four studies comparing PRN, T&E and fixed
monthly dosing with ranibizumab indicated that T&E dosing offers
similar visual outcomes to monthly dosing, while reducing injection
burden.79 In contrast, improvements in VA over 12 months were
significantly lower with PRN dosing than with a T&E regimen.79
It is important to note that while good visual outcomes can be
achieved with extended injection intervals, recent findings indicate
that there is a positive and clinicallymeaningful correlation between
the number of injections and VA outcomes22 and that injection
frequency in the first year is an important contributor to VA
gains.22 23
Initial loading doses
Regardless of treatment regimen, RWE has demonstrated the
importance of receiving initial loading doses for achieving opti-
mal outcomes for patients with nAMD. Typically, gains in VA are
observed in the first 3 months of treatment with initial loading
doses, and the aim of subsequent treatment (regardless of regi-
men) is to maximise and maintain initial gains.80 In the large,
observational RAINBOW study, treatment-naïve patients receiv-
ing full initial intravitreal aflibercept loading doses achieved sig-
nificant gains in VA compared with baseline at Year 1, with no
improvement in those who did not receive the initial loading
doses (+7.1 letters in regular cohort vs −1.1 letters in irregular
cohort who did not receive initial loading doses, at 12 months).56
DISCUSSION
The discovery of anti-VEGF therapies led to a paradigm shift in
the management of nAMD, as these became the first treatment
option associated with improvements in VA in RCTs.15 16 Since
their initial approval, anti-VEGF treatment regimens have been
adapted by physicians to meet patients’ needs and healthcare
resource availability. Regimens have evolved in parallel with
emerging RWE, with the aim of optimising visual outcomes and
reducing treatment burden. Here, we identify and describe the
growing body of evidence supporting the effectiveness of anti-
VEGF therapy for the treatment of nAMD in routine clinical
practice.
Initial fixed monthly ranibizumab regimens were associated
with good efficacy and tolerability in RCTs.15 16 However,
these outcomes were not mirrored in early real-world studies
due to under-treatment resulting from treatment burden. PRN
regimens offered the opportunity to achieve visual gains at Year 1,
with a reduced number of injections, but visual outcomes were
suboptimal andmonthly appointments were required, even when
an injection was not needed, which compromised the reduction
in treatment burden.29 30 In contrast, intravitreal aflibercept in
a bimonthly regimen after three initial loading doses was asso-
ciated with good visual outcomes and tolerability in both RCTs
and real-world studies.19 48–56
The opportunity to reduce patient, physician and clinic burden
and optimise visual outcomes, led to the investigation of anti-
VEGF T&E regimens. Recently, a growing body of evidence has
emerged from RCTs and real-world studies supporting the effec-
tiveness of T&E regimens with anti-VEGFs.58 62 81 Evidence so
far indicates that T&E regimens are associated with improved
visual outcomes compared with PRN regimens at Year 1 and
beyond, with potentially fewer clinic visits than fixed monthly
or PRN dosing.30 79 These findings demonstrate the clinical and
quality of life benefits T&E regimens offer to patients, clinics and
physicians, compared with PRN regimens.
Our comprehensive review included more than 100 articles
describing treatment regimens and outcomes with anti-VEGF
treatment for nAMD in real-world clinical practice and reflects
the currently available body of evidence. A limitation to the
analysis may arise from heterogeneity in the methods and popu-
lations of the included studies, and the relatively small sample size
and retrospective nature of many of the studies, which may make
generalisation inappropriate and limit definitive comparisons.
Although a number of network meta-analyses have been con-
ducted using clinical trial data from RCTs to assess the efficacy
and safety of anti-VEGF treatments,82 83 the present literature
review differs in that it offers insights into the use of anti-VEGF
treatment of nAMD in a real-world setting and how RWE has
actively informed new, pragmatic, treatment strategies.
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In conclusion, RWE has helped to shape and improve treat-
ment strategies in nAMD in clinical practice, and demonstrates
that T&E regimens can optimise visual outcomes and reduce
treatment burden for patients with nAMD.
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